A Phase 2 interventional study of Placebo matching BMS-945429 and BMS-945429 in Arthritis, Psoriatic, sponsored by CSL Behring. Completed at 49 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-05.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 97th largest by enrollment of the 158 interventional ones that give a count, is one of 6 that started in 2011, is one of 31 in phase 2, and was the 36th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
Medical College of Wisconsin · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 35 · Phase 3 73 · Phase 4 18
First in 1991; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 237 across the 158 interventional studies, 325 across the 34 observational. Of the 128 that completed or were terminated, 79 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 193 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 1 study filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Psoriatic with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 16 to your calendar (.ics) → With an account.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic Disease modifying anti-rheumatic drugs (DMARDs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: Placebo matching BMS-945429
Biological: BMS-945429
Biological: BMS-945429
Biological: BMS-945429
Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20)
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Time frame: At 16 weeks
Percent of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response Rate
To calculate the PASI score, the psoriasis plaques found on each body region are graded for their combined redness, thickness, and scaliness. The severity of the plaques in each region is graded on a 0 to 4 scale, with 0 meaning no involvement and 4 meaning severe involvement. Next, the amount of surface area on each body region that is covered by the plaques is calculated. The total surface area affected by psoriasis is graded from 0 to 6, with 0 meaning no involvement and 6 meaning greater than 90 percent of the region covered in plaques. These grades are then fed into an equation to determine the patient's PASI score. The PASI score then is used as a clinical assessment of the patient's psoriasis involvement. A person free of psoriasis has a score of 0 and the score could be as high as 72. PASI 75 means that the person's PASI score dropped by 75 percent as a result of the psoriasis treatment.
Time frame: Week 16 and Week 24
Percent of Participants Achieving ACR50 and ACR70 Response Rate
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Time frame: Week 16 and Week 24
Percent of Participants Achieving ACR20 Response Rate at Week 24
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Time frame: Week 24
Percent of Participants Achieving a Health Assessment Questionnaire (HAQ) Response
For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). There are 20 questions in eight categories of functioning - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The highest component score in each category determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score to the level of 2 to more accurately represent underlying disability. The eight category scores are averaged into an overall HAQ score on a scale from zero (no disability) to three (completely disabled). The scale is not truly continuous but has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 ... 3). Response is measured by a reduction of at least 0.3 unit from baseline in HAQ index.
Time frame: Weeks 16 and Week 24
Mean Change From Baseline at Week 16 in Short Form (36) [SF-36] Scores
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.
Time frame: Baseline and Week 16
Mean Change From Baseline at Week 24 in SF-36 Scores
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.
Time frame: Baseline and Week 24
Number of Participants With Anti-clazakizumab Antibodies
Time frame: Up to 24 weeks
| Milestone | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| Started | 41 | 41 | 42 | 41 |
| Completed | 38 | 40 | 38 | 33 |
| Not completed | 3 | 1 | 4 | 8 |
| Withdrew: Lack of efficacy | 2 | 0 | 3 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 5 |
| Withdrew: Request to discontinue treatment | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 |
| Withdrew: No longer met study criteria | 0 | 1 | 1 | 0 |
| Milestone | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| Started | 38 | 40 | 37 | 32 |
| Completed | 36 | 39 | 37 | 28 |
| Not completed | 2 | 1 | 0 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
| percentage of participants | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) | 29.3 | 46.3 | 52.4 | 39.0 |
To calculate the PASI score, the psoriasis plaques found on each body region are graded for their combined redness, thickness, and scaliness. The severity of the plaques in each region is graded on a 0 to 4 scale, with 0 meaning no involvement and 4 meaning severe involvement. Next, the amount of surface area on each body region that is covered by the plaques is calculated. The total surface area affected by psoriasis is graded from 0 to 6, with 0 meaning no involvement and 6 meaning greater than 90 percent of the region covered in plaques. These grades are then fed into an equation to determine the patient's PASI score. The PASI score then is used as a clinical assessment of the patient's psoriasis involvement. A person free of psoriasis has a score of 0 and the score could be as high as 72. PASI 75 means that the person's PASI score dropped by 75 percent as a result of the psoriasis treatment.
| percentage of participants | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| week 16 | 14.6 | 12.2 | 16.7 | 4.9 |
| week 24 | 12.2 | 19.5 | 28.6 | 12.2 |
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
| percentage of participants | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| ACR50 (16 weeks) | 7.3 | 29.3 | 35.7 | 17.1 |
| ACR50 (24 weeks) | 14.6 | 34.1 | 35.7 | 24.4 |
| ACR70 (16 weeks) | 2.4 | 17.1 | 14.3 | 4.9 |
| ACR70 (24 weeks) | 4.9 | 19.5 | 23.8 | 12.2 |
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
| percentage of participants | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| Percent of Participants Achieving ACR20 Response Rate at Week 24 | 34.1 | 56.1 | 57.1 | 39.0 |
For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). There are 20 questions in eight categories of functioning - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The highest component score in each category determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score to the level of 2 to more accurately represent underlying disability. The eight category scores are averaged into an overall HAQ score on a scale from zero (no disability) to three (completely disabled). The scale is not truly continuous but has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 ... 3). Response is measured by a reduction of at least 0.3 unit from baseline in HAQ index.
| percentage of participants | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| week 16 | 36.6 | 48.8 | 45.2 | 39.0 |
| week 24 | 26.8 | 51.2 | 47.6 | 36.6 |
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.
| score on a scale | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| Mental component | 1.4 ± 1.507 | 1.2 ± 1.502 | 3.7 ± 1.478 | 1.1 ± 1.516 |
| Physical component | 4.4 ± 1.236 | 6.5 ± 1.236 | 4.6 ± 1.217 | 4.1 ± 1.248 |
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.
| score on a scale | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| Mental component | 3.6 ± 1.646 | 1.4 ± 1.538 | 3.9 ± 1.548 | 2.1 ± 1.689 |
| Physical component | 4.9 ± 1.420 | 8.2 ± 1.360 | 5.7 ± 1.363 | 6.4 ± 1.461 |
| participants | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|
| Number of Participants With Anti-clazakizumab Antibodies | 1 | 0 | 1 |
Collected over Up to 24 weeks per participant. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/41 (0%) | 2/41 (4.9%) | 19/41 (46.3%) |
| Clazakizumab (25mg) | 0/41 (0%) | 2/41 (4.9%) | 22/41 (53.7%) |
| Clazakizumab (100mg) | 0/42 (0%) | 2/42 (4.8%) | 20/42 (47.6%) |
| Clazakizumab (200mg) | 0/41 (0%) | 4/41 (9.8%) | 27/41 (65.9%) |
| Event | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| HemiparesisNervous system disorders | 0/41 | 0/41 | 0/42 | 1/41 |
| HypoaesthesiaNervous system disorders | 0/41 | 0/41 | 0/42 | 1/41 |
| Adute myocardial infarctionCardiac disorders | 0/41 | 0/41 | 0/42 | 1/41 |
| BradycardiaCardiac disorders | 0/41 | 1/41 | 0/42 | 0/41 |
| Intervertebral disc disorderMusculoskeletal and connective tissue disorders | 0/41 | 0/41 | 0/42 | 1/41 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/41 | 0/41 | 0/42 | 1/41 |
| Bladder neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/41 | 0/41 | 0/42 | 0/41 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/41 | 0/41 | 0/42 | 0/41 |
| Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/41 | 0/41 | 0/42 | 0/41 |
| Chest painGeneral disorders | 0/41 | 1/41 | 0/42 | 0/41 |
| Event | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/41 | 9/41 | 6/42 | 8/41 |
| NasopharyngitisInfections and infestations | 1/41 | 6/41 | 2/42 | 4/41 |
| Upper respiratory tract infectionInfections and infestations | 6/41 | 0/41 | 3/42 | 1/41 |
| Aspartate aminotransferase increasedInvestigations | 0/41 | 6/41 | 4/42 | 4/41 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/41 | 5/41 | 2/42 | 5/41 |
| HypertensionVascular disorders | 1/41 | 2/41 | 2/42 | 5/41 |
| PharyngitisInfections and infestations | 4/41 | 4/41 | 1/42 | 1/41 |
| Urinary tract infectionInfections and infestations | 2/41 | 4/41 | 1/42 | 0/41 |
| GastritisGastrointestinal disorders | 1/41 | 4/41 | 0/42 | 1/41 |
| Injection site reactionGeneral disorders | 1/41 | 4/41 | 1/42 | 2/41 |
| Age, Categorical(Participants) | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 38 | 34 | 40 | 40 | 152 |
| >=65 years | 3 | 7 | 2 | 1 | 13 |
| Age, Continuous(years) | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) | Total |
|---|---|---|---|---|---|
| Mean | 48.0 ± 10.53 | 49.8 ± 14.05 | 49.3 ± 10.84 | 44.7 ± 13.75 | 47.9 ± 12.43 |
| Sex: Female, Male(Participants) | Placebo | Clazakizumab (25mg) | Clazakizumab (100mg) | Clazakizumab (200mg) | Total |
|---|---|---|---|---|---|
| Female | 23 | 23 | 20 | 20 | 86 |
| Male | 18 | 18 | 22 | 21 | 79 |
The record gives a start of Dec 2011, a primary completion of Jun 2013 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2021, 8 years 5 months after primary completion. A results delay was requested in Jul 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clazakizumab